Eli Lilly And Co patent expiration

1. Axiron patent expiration

AXIRON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071075 ELI LILLY AND CO Dermal penetration enhancers and drug delivery systems involving the same
Feb, 2017

(7 years ago)

US6299900 ELI LILLY AND CO Dermal penetration enhancers and drug delivery systems involving same
Feb, 2017

(7 years ago)

US6923983 ELI LILLY AND CO Transdermal delivery of hormones
Feb, 2017

(7 years ago)

US6818226 ELI LILLY AND CO Dermal penetration enhancers and drug delivery systems involving same
Feb, 2017

(7 years ago)

US8784878 ELI LILLY AND CO Transdermal delivery rate control using amorphous pharmaceutical compositions
Jul, 2023

(1 year, 2 days ago)

US8993520 ELI LILLY AND CO Method and composition for transdermal drug delivery
Jun, 2026

(1 year, 10 months from now)

US9180194 ELI LILLY AND CO Method and composition for transdermal drug delivery
Jun, 2026

(1 year, 10 months from now)

US9289586 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US8807861 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US8419307 ELI LILLY AND CO Spreading implement
Feb, 2027

(2 years from now)

US8435944 ELI LILLY AND CO Method and composition for transdermal drug delivery
Sep, 2027

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 23, 2013

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 23 November, 2010

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; A method of transdermally delivering testosterone; A method of increasing t...

Dosage: SOLUTION, METERED

How can I launch a generic of AXIRON before it's drug patent expiration?
More Information on Dosage

AXIRON family patents

Family Patents

2. Humalog Kwikpen patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6551992 ELI LILLY AND CO Stable insulin formulations
Jun, 2018

(6 years ago)

US6034054 ELI LILLY AND CO Stable insulin formulations
Jun, 2018

(6 years ago)

US7291132 ELI LILLY AND CO Medication dispensing apparatus with triple screw threads for mechanical advantage
Aug, 2024

(25 days from now)




Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient

Market Authorisation Date: 26 May, 2015

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.

Dosage: SOLUTION

More Information on Dosage

HUMALOG KWIKPEN family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Mounjaro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION

More Information on Dosage

MOUNJARO family patents

Family Patents

4. Mounjaro (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(6 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(6 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION

More Information on Dosage

MOUNJARO (AUTOINJECTOR) family patents

Family Patents

5. Olumiant patent expiration

OLUMIANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
May, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Mar, 2029

(4 years from now)

US11806555 ELI LILLY AND CO Methods for treating hair loss disorders
Nov, 2031

(7 years from now)

US9737469 ELI LILLY AND CO Methods for treating hair loss disorders
Nov, 2031

(7 years from now)

US11045474 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
Nov, 2032

(8 years from now)

US9089574 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
Nov, 2032

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 31, 2023
New Indication(I-891) May 10, 2025
New Indication(I-890) Jun 13, 2025

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: 31 May, 2022

Market Authorisation Date: 08 October, 2019

Treatment: Treatment of rheumatoid arthritis; Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-i...

Dosage: TABLET

How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage

OLUMIANT family patents

Family Patents

6. Prozac patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6960577 ELI LILLY AND CO Combination therapy for treatment of refractory depression
Nov, 2017

(6 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-589) Mar 19, 2012
New Patient Population(NPP) Jul 26, 2016

Drugs and Companies using FLUOXETINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 December, 1992

Treatment: Prozac and olanzapine in combination for the acute treatment of treatment resistant depression in adults

Dosage: CAPSULE

How can I launch a generic of PROZAC before it's drug patent expiration?
More Information on Dosage

PROZAC family patents

Family Patents

7. Reyvow patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Feb, 2028

(3 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Mar, 2023

(1 year, 3 months ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: 01 February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET

More Information on Dosage

REYVOW family patents

Family Patents

8. Verzenio patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7855211 ELI LILLY AND CO Protein kinase inhibitors
Dec, 2029

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-768) Feb 26, 2021
New Chemical Entity Exclusivity(NCE) Sep 28, 2022
New Patient Population(NPP) Oct 12, 2024
New Indication(I-877) Oct 12, 2024

Drugs and Companies using ABEMACICLIB ingredient

NCE-1 date: 28 September, 2021

Market Authorisation Date: 28 September, 2017

Treatment: As monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the...

Dosage: TABLET

More Information on Dosage

VERZENIO family patents

Family Patents

9. Zepbound patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11918623 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 08, 2026
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...

Dosage: SOLUTION

More Information on Dosage

ZEPBOUND family patents

Family Patents

10. Zepbound (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(6 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(6 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)

US11918623 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 08, 2026
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...

Dosage: SOLUTION

More Information on Dosage

ZEPBOUND (AUTOINJECTOR) family patents

Family Patents